Description
Trenbolone Acetate (Tren A, Finaplix) is the short-acting acetate ester of Trenbolone, a 19-nortestosterone derivative with potent androgenic and anabolic activity. Structurally Trenbolone arises from modification of Nandrolon with additional double bonds that make the molecule resistant to aromatization and 5α-reduction.
Per study reports Trenbolone binds with high affinity to the androgen receptor, with values substantially above testosterone. The substance is not aromatized to estradiol, excluding the classical E2-mediated water retention effect. Trenbolone also acts progestagenically, which can lead to prolactin-mediated effects.
The acetate ester form has an elimination half-life of about 3 days and requires research protocols with injections every 1-2 days for stable plasma levels. Compared to longer Tren esters, the rapid profile allows faster cycle adjustments and shorter taper phases.
Known effects in studies and recreational research reports are more pronounced than under classical testosterone: Tren cough (cough reflex right after injection), night sweats, sleep disturbances, tachycardia, aggression, markedly elevated prolactin levels with potential galactorrhea research findings, unfavorable lipid profile. Hepatotoxicity is lower than under oral 17α-methyl steroids but not negligible.
Trenbolone has been on the WADA banned list since the beginning of doping controls.
You can order Trenbolone Acetate as an oily injection solution in 10-pack at 100mg/ml.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Trenbolone Acetate is considered the most aggressive classical anabolic in recreational research - the effects documented in studies and user reports are markedly more pronounced than with classical testosterone.
Documented in studies and the application literature:
- Progestagenic and prolactinergic action: Trenbolone acts progestagenically and drives prolactin levels up. Prolactin-mediated effects up to galactorrhea research findings are documented. Trenbolone does not aromatize.
- Suppression of endogenous production: Trenbolone strongly suppresses endogenous testosterone production. Testicular atrophy and reduced fertility are documented, a separate test base is mandatory in research practice.
- Acute reactions: user reports describe the Tren cough right after injection, night sweats, sleep disturbances, tachycardia and aggression.
- Cardiovascular and liver: the literature describes an unfavorable lipid profile, cardiac effects are documented in preclinical models. Hepatotoxicity is lower than under oral 17-alpha-methyl steroids but not negligible.
Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- 17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate - American Journal of Physiology-Endocrinology and Metabolism 2011, Yarrow et al: shows in castrated rats that Trenbolone Enanthate drives anabolic effects on muscle without aromatization and with reduced prostate growth.
- Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor - APMIS 2000, Bauer et al: quantifies the binding affinities of 17β-trenbolone for the human androgen receptor and the bovine progestin receptor, providing the biochemical basis for the progestagenic component.
- Differences in the biotransformation of a 17β-hydroxylated steroid, trenbolone acetate, in rat and cow - Xenobiotica 1981, Pottier et al: investigates the metabolism of Trenbolone Acetate in rat and cow and documents rapid hydrolysis of the acetate ester to free 17β-trenbolone.
- Trenbolone Improves Cardiometabolic Risk Factors and Myocardial Tolerance to Ischemia-Reperfusion in Male Rats With Testosterone-Deficient Metabolic Syndrome - Endocrinology 2016, Donner et al: preclinical study documenting trenbolone effects on body composition, lipid profile and cardiac ischemia-reperfusion tolerance.
- ‘My mind pretty much went to mush’: A qualitative exploration of trenbolone in the performance and image enhancing drug community - Drug and Alcohol Review 2023, Piatkowski et al: qualitative interview study with user reports on psychological effects and behavioural changes under trenbolone.
